He & She MD Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

An ingredient name is not a complete evidence trail. At He & She MD, semaglutide and tirzepatide appear across compounded-treatment plans, injectable product pages and oral-tablet listings. Those pages document a commercial offering, but they do not establish that every formulation has the same clinical evidence—or that every advertised price describes the same purchase. For adults considering the service, the central question is how clearly its treatment, prescribing and payment claims connect to a specific product and a responsible care team.

The public pages consulted October 19, 2026, provide meaningful detail: named clinical and pharmacy organizations, billing schedules, shipping restrictions and a questionnaire-based intake process. They also contain material inconsistencies. This documentary review separates the provider’s statements from independent clinical context, without treating either marketing claims or missing information as proof of treatment quality. The useful starting point is what public provider documents can prove: they can describe an offer, but they cannot substitute for independently measured outcomes or a patient’s actual prescription and purchase terms.

At a glance

Documented treatment offering: He & She MD advertises compounded semaglutide and tirzepatide, injectable and oral product pages, and certain FDA-approved brands when clinically appropriate and available.
Sources: [6] [13] [11] [7] [12]
Annual-price condition: The semaglutide injection page’s starting price of $99 per month requires purchasing 12 months of supply; the plans page lists $1,188 paid annually.
Sources: [13] [6]
Material pricing disagreement: Nonannual prices on the injectable product pages exceed those on the plans page. Homepage notes also describe higher six-month renewal charges.
Sources: [6] [13] [11] [9]
Clinical responsibility needs clarification: The FAQ identifies Wasef Health, PC, while terms revised in 2022 describe a technology platform connecting patients with Beluga Health or similar affiliated entities.
Sources: [9] [8]
GLP-1 shipping boundaries: The provider advertises GLP-1 shipping to every U.S. state except Louisiana, no PO-box deliveries and free shipping; this does not independently establish clinical availability for every product.
Sources: [6] [9]

Begin with the product, not the ingredient name

He & She MD describes itself as a telehealth clinic covering weight loss, longevity, hormone therapy and performance health. Its weight-management materials advertise compounded semaglutide and tirzepatide, alongside Wegovy, Ozempic, Zepbound and Mounjaro when clinically appropriate and available. That establishes a broader advertised offering than a single compounded subscription. It does not establish which product an applicant will receive, whether a brand option is currently obtainable or whether the published compounded-plan prices cover any branded prescription.

The product pages distinguish subcutaneous semaglutide and tirzepatide injections from oral tablets bearing those ingredient names. However, the consulted documentation does not specify the oral products’ complete formulations, added ingredients, manufacturers or product-specific regulatory status. That gap matters when assessing evidence: a shared ingredient name does not identify an identical finished medicine. The oral listings therefore require more clarification than a simple comparison of tablet and injection convenience.

The provider’s own compounding article acknowledges that compounded medications are not FDA approved and have not undergone FDA review for safety, effectiveness or quality. FDA approval belongs to a specific product—not to this platform, a pharmacy or every formulation of a molecule. Our guide to approved medicines and compounded preparations explains that distinction. Nonapproval alone does not demonstrate clinical inequivalence, but neither does a familiar ingredient establish equivalence.

Sources: [9] [6] [13] [11] [7] [12] [10] [1]

Clinical research does not measure this service’s results

STEP 1 and SURMOUNT-1 provide evidence about particular studied subcutaneous treatments, populations and treatment periods. They are not studies of He & She MD, its dispensing partners or its oral and compounded offerings. Their results cannot establish how much weight this provider’s patients lose, how consistently follow-up occurs or how its formulations perform. No independently verified provider-specific clinical outcomes are established by the consulted documentation.

This distinction is especially important for the oral listings. Evidence for a studied injectable treatment cannot simply be transferred to a tablet advertised under the same ingredient name. Nor should figures from separate trials become a head-to-head ranking of this provider’s options. The broader principle—a clinical trial is not a company performance report—lets readers recognize meaningful drug research without granting unmeasured claims about a particular service.

FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a categorical legal conclusion about this provider. It does identify a useful consultation question: why is the proposed formulation appropriate for this patient? NIDDK also emphasizes benefits, side effects, other medicines, health conditions and costs when discussing medication selection with a clinician.

Sources: [3] [4] [1] [2]

Identify who is actually providing the medical care

The FAQ names Wasef Health, PC, care of Michael Wasef, MD, as the clinical provider. It lists contact@wasef-health.com and an office address at 5260 78th Ave N, PO Box 1697, Pinellas Park, Florida. Separately, the plans page presents Ozita Cooper, MD, as chief medical officer and describes her as dual board-certified in obesity and emergency medicine. These are site statements, not independently verified credentials or confirmation of who would treat a particular applicant.

The terms, carrying a 2022 revision date, describe a different organizational arrangement. They say He and She MD does not itself provide medical services, instead supplying a technology platform for access to professionals employed or contracted by Beluga Health, P.A., or similar affiliated entities. Those descriptions might reflect different roles or different periods, but the public documentation does not resolve their relationship. Patients need the current treating entity and clinician identified before relying on either description.

The intake materials promise review by a licensed, board-certified U.S. physician, described as an MD or DO. That is a more specific claim than generic access to a clinician, but it remains an advertised service characteristic. A useful confirmation would identify the actual prescriber, the entity maintaining the medical record and the contact responsible for clinical concerns after dispensing. A prominent medical-director biography does not answer those operational questions.

Sources: [9] [8] [6]

The intake process is documented better than its clinical detail

He & She MD advertises a free online assessment taking about five minutes, with questions about goals and medical history. The plans page separately places provider review at approximately 24 hours. These describe different stages: five minutes is estimated questionnaire completion, not a completed medical evaluation, and the review estimate is not a delivery promise. The site says payment occurs only if medication is prescribed and that applicants who are not candidates pay nothing.

The terms require users to be at least 18 and located in a state where the relevant service operates. An educational article discusses BMI of 30 or higher, or 27 or higher with certain weight-related health problems, while emphasizing individualized assessment. Those statements do not guarantee admission or a prescription. The consulted materials also do not establish whether initial or periodic laboratory testing is required, who orders it or whether testing adds a separate charge.

The documentation is less clear about what happens when a questionnaire needs clarification, whether a live appointment becomes necessary or what response time applies to clinical messages. Those are service-process unknowns, not evidence that evaluation is absent. Before enrolling, a reader can ask how the clinician confirms the proposed product, reviews current medicines and explains follow-up responsibilities. That produces more useful information than treating a short intake estimate as a measure of clinical thoroughness.

Sources: [8] [6] [5] [2]

Conflicting prices weaken purchase clarity

The plans page provides explicit collection intervals rather than only monthly equivalents. For compounded semaglutide, it lists $834 every six months, $447 every three months, $199 billed monthly or $1,188 annually. Tirzepatide is listed at $1,194 every six months, $627 every three months, $299 billed monthly or $1,908 annually. These are alternatives, not a requirement that every patient prepay annually. The injectable product pages, however, publish different nonannual prices, as the table shows.

The semaglutide injection page qualifies its starting-at $99 monthly price as a purchase of 12 months of supply. It also advertises the same price at every dose, no membership fee, no insurance requirement and HSA/FSA acceptance; that last statement is not an independent tax-eligibility determination. The homepage simultaneously displays an annual-based $99 offer and an offer-ended notice. Neither the available annual listing nor a monthly equivalent resolves that promotional ambiguity.

Homepage notes add another distinction: $199 monthly for the first six months, followed by $1,734 per six-month renewal, equivalent to $289 monthly; and $139 monthly initially, followed by $1,194 per six-month renewal, equivalent to $199 monthly. The site advertises respective savings of $540 and $360, while plan cards also advertise savings. The unresolved task is matching each offer to the actual purchase—not calculating new savings or assuming the introductory amount continues.

Advertised prices differ by page. Monthly figures are not necessarily monthly collection amounts.
Advertised option	Compounded plans page	Corresponding injectable product page
Semaglutide, annual	$99/month; $1,188 paid annually	$99/month for 12 months
Semaglutide, nonannual	6 months: $139/month, $834 collected; 3 months: $149/month, $447 collected; monthly: $199	6 months: $199/month; 3 months: $219/month; 1 month: $249
Tirzepatide, annual	$159/month; $1,908 paid annually	$159/month for 12 months
Tirzepatide, nonannual	6 months: $199/month, $1,194 collected; 3 months: $209/month, $627 collected; monthly: $299	6 months: $289/month; 3 months: $309/month; 1 month: $339

Sources: [6] [13] [11] [9]

Oral pricing and included services need separate confirmation

The oral semaglutide page lists $209 per month for 12 months, $239 for six, $259 for three and $279 for one. Its table is incongruously labeled as injectable semaglutide pricing. The oral tirzepatide page lists $269 per month for 12 months, $289 for six, $309 for three and $339 for one—but labels the table as injectable sermorelin pricing. These are documented advertised amounts, not sufficiently clear confirmation of the formulation being purchased or its collection schedule.

The plans page says every plan includes medication if prescribed, injection supplies, free shipping, ongoing provider support and unlimited messaging, with no membership fees. The site does not accept insurance, supply superbills or communicate with insurers. Patients may independently submit receipts, but reimbursement is not guaranteed. A $25 first-treatment promotion requires consultation, applies to the first prescribed treatment and is subject to eligibility; it should not be treated as an automatic discount for every applicant.

Cancellation and refunds are less clearly documented. Older terms allow patients to pause membership auto-payments through the secure account or support@heandshemd.com. They also state that the provider may cancel the membership without notice after eight or more consecutive weeks in “On-demand” status without scheduling a continuation visit. These provisions do not establish patient-initiated cancellation or refund rights for current GLP-1 plans, which advertise no membership fees. The consulted terms do not establish a complete current refund policy. Nor does buying a year establish shipment frequency, simultaneous delivery of a year’s medication or a minimum commitment beyond the actual purchase terms.

Sources: [7] [12] [6] [8]

Pharmacy names do not resolve the fulfillment chain

He & She MD names Specialty Medical Drugstore LLC, doing business as GoGoMeds, and F&F Pharmacies Inc, doing business as Jungle Jim’s Pharmacy, as prescription-fulfillment partners. It does not clearly identify which pharmacy prepares each compounded formulation. Dispensing a prescription and compounding its contents are different responsibilities; identifying a fulfillment partner does not establish the preparation source, product-specific quality evidence or FDA approval.

The FAQ says Jungle Jim’s holds licenses in 44 states, then lists ten excluded states: California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia and Delaware. It also says that pharmacy cannot dispense sterile compounds. The numerical and operational descriptions do not clearly align with the broader promise of GLP-1 shipping everywhere except Louisiana. Another partner might cover a gap, but the consulted pages do not establish that arrangement.

The service advertises free expedited shipping, discreet packages, no PO boxes and emailed tracking. A delivery stage is labeled two to three days without a clear starting point; it should not be read as guaranteed arrival after intake. A compounding article says shipments usually include cold packaging. FDA explicitly advises not using injectable GLP-1 medication that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. That instruction is more consequential than assuming expedited shipping guarantees temperature control.

Sources: [6] [9] [10] [1]

Support promises need clinical and privacy boundaries

The provider advertises an app for tracking progress and adjusting the plan, along with nutritional guidance and habit coaching. Plans include ongoing support and unlimited messaging, while the semaglutide injection page advertises 24/7 support. These statements describe access features, not a documented schedule of clinical reassessment. The consulted pages do not establish guaranteed clinician response times, professional coverage hours or Spanish-language care and interpretation.

The telemedicine consent supplies an important boundary: asynchronous services are not emergency services, and personal data will not be monitored around the clock. That is not necessarily incompatible with administrative support being available 24/7, but the two should not be conflated. Patients need to know which channel reaches a treating professional, what routine response interval applies and how side-effect concerns are handled. Our guide to clinical follow-up beyond renewal notices explains why access and reassessment are separate questions.

Privacy statements also require channel-specific reading. Although the commercial FAQ describes information as fully encrypted, the terms explicitly warn that text messages and email are unencrypted and may be intercepted. A secure account should not be assumed to make every communication method equally protected. Together, these limitations suggest asking for a written follow-up plan and preferred clinical messaging channel, rather than interpreting unlimited messaging as continuous medical observation.

Sources: [9] [13] [6] [8] [2]

Questions & answers

Can I buy He & She MD semaglutide for $99 one month at a time?

The documented $99 starting price is not a standalone monthly option. The injection page ties it to purchasing 12 months of supply, and the plans page specifies $1,188 annually. A separate monthly plan is advertised at $199, while the injection page lists $249 for one month. Confirm the controlling price and collection schedule before authorizing payment.

Sources: [13] [6]

Are the oral products documented as equivalent to the injections?

No equivalence is established by the consulted materials. The site advertises oral semaglutide and tirzepatide tablets, but does not clearly identify their complete formulations, manufacturers or specific regulatory status. Their pricing tables also carry mismatched product labels. Ask for the exact prescription and preparation details; injectable trial results do not establish outcomes for these oral offerings.

Sources: [7] [12] [3] [4]

Who should I contact about the clinical organization?

The FAQ identifies Wasef Health, PC, and provides contact@wasef-health.com. Older terms instead describe access through Beluga Health or similar affiliated professional entities. Ask which organization will deliver your care, maintain your record and handle clinical follow-up. The site’s named medical director does not by itself identify your treating prescriber.

Sources: [9] [8] [6]

Will He & She MD bill my insurance or help with reimbursement?

The provider says it does not accept insurance, provide superbills or communicate with insurance carriers. You may submit receipts independently after paying directly, but reimbursement is not guaranteed. HSA/FSA acceptance is separately advertised on the semaglutide injection page; that statement should not be read as confirmation of an individual account’s reimbursement or tax treatment.

Sources: [6] [13]

Does the advertised shipping coverage guarantee my prescription can be filled?

No. The provider advertises GLP-1 shipping to all states except Louisiana, but clinical availability and pharmacy authorization are separate questions. Its Jungle Jim’s description lists additional state restrictions and says that pharmacy cannot dispense sterile compounds. Ask which pharmacy will dispense your exact product in your state, and which pharmacy prepares it if compounded.

Sources: [6]

Can I cancel a prepaid plan and receive the unused balance?

The consulted documentation does not establish a complete current GLP-1 cancellation or refund policy. Older membership terms describe pausing automatic payments through an account or support email, but current plans advertise no membership fees. A pause clause is not a refund promise. Obtain written terms covering renewals, cancellation, already-dispensed medication and any unused prepaid balance before choosing a longer billing interval.

Sources: [8] [6]

Our assessment

He & She MD documents a substantive telehealth weight-management offering: multiple advertised formulations, conditional prescribing, named fulfillment partners, explicit payment intervals and included support. Those details give prospective patients concrete questions to ask. They do not establish independently verified clinical outcomes, formulation equivalence or consistent access across every advertised state. The most consequential weaknesses are conflicting prices, incomplete oral-product identification, differing clinical-entity descriptions and unclear current cancellation terms. A practical next step is to obtain one written summary identifying the prescribed product, treating organization, preparing and dispensing pharmacies, initial charge, renewal charge, shipment cadence and refund boundaries. If those answers reconcile the public inconsistencies, the offering becomes easier to evaluate. Until then, the documentation supports neither dismissing the service outright nor treating its marketing as a complete account of the care and purchase.

Visit He & She MD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

He & She MD Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

At a glance

01Begin with the product, not the ingredient name

02Clinical research does not measure this service’s results

03Identify who is actually providing the medical care

04The intake process is documented better than its clinical detail

05Conflicting prices weaken purchase clarity

06Oral pricing and included services need separate confirmation

07Pharmacy names do not resolve the fulfillment chain

08Support promises need clinical and privacy boundaries